AUTL · Autolus Therapeutics plc

Autolus Therapeutics plc reported strong Q1 FY2026 results reflecting AUCATZYL commercialization momentum. Revenue rose 191.9% year-over-year to $26.2 million from $9.0 million, primarily due to an increase in the number of AUCATZYL doses administered in territories where the company commercializes the product, including the U.S. and new U.K. launch. This ramp-up marks a key inflection as the company transitions from clinical development to sustained revenue generation.

Gross profit achieved a milestone at $1.6 million, flipping from a $9.0 million loss in the prior year, representing a 118.4% improvement. This shift occurred because cost of sales for the newly launched product does not yet include full manufacturing costs until initial pre-launch raw materials inventory is depleted. Certain manufacturing expenses prior to FDA approval were classified as research and development, creating zero-cost inventories that lowered the cost of sales percentage relative to net sales. Gross margin stood at 6.3%, with future periods expected to reflect more normalized manufacturing costs alongside potential excess or obsolete inventory adjustments and intangible amortization.

Cash flow from operations improved to -$65.3 million used from -$75.6 million, with free cash flow at -$68.0 million after $2.7 million in capital expenditures, down sharply from $8.2 million prior year. This reflects working capital benefits from revenue growth and disciplined capex as manufacturing scale-up completes post-launch. Since inception, the company has incurred operating losses and negative cash flows, consistent with biotech commercialization dynamics. Rebates and chargebacks in the U.S. are estimated using product sales data, payor mix, care settings, and discount rates, introducing judgment in revenue recognition.

The company anticipates SG&A increases to support AUCATZYL commercialization and product candidate development, while current liquidity meets obligations for at least one year without additional funding needs. The AGC Agreement provides robust governance for manufacturing order fulfillment, regulatory support, and risk allocation, underpinning supply chain reliability.